ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00343252
Recruitment Status : Completed
First Posted : June 22, 2006
Results First Posted : July 12, 2010
Last Update Posted : May 26, 2011
Sponsor:
Information provided by:
Eli Lilly and Company

June 20, 2006
June 22, 2006
June 8, 2010
July 12, 2010
May 26, 2011
June 2006
June 2009   (Final data collection date for primary outcome measure)
Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint [ Time Frame: 6 Months ]
24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 6-month last observation carried forward (LOCF) endpoint.
Proportion of patients treated with daily teriparatide compared with weekly risedronate who have at least a 30% improvement in the 11-point numeric rating scale evaluating back pain from baseline to Month 6.
Complete list of historical versions of study NCT00343252 on ClinicalTrials.gov Archive Site
  • Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 12-Month Endpoint [ Time Frame: 12 Months ]
    24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 12-month last observation carried forward (LOCF) endpoint.
  • Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 6-Month Endpoint [ Time Frame: 6 Months ]
    24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 6-month last observation carried forward (LOCF) endpoint.
  • Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 12-Month Endpoint [ Time Frame: 12 Months ]
    24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 12-month last observation carried forward (LOCF) endpoint.
  • Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 6 Months [ Time Frame: Days 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300 ]
    Time to first occurrence of >= 30% pain reduction in worst back pain from baseline to 6 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.
  • Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 12 Months [ Time Frame: Days 0, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600 ]
    Time to first occurrence of >= 30% pain reduction in worst back pain from baseline to 12 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.
  • Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 6 Months [ Time Frame: Days 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300 ]
    Time to first occurrence of >=30% pain reduction in average back pain from baseline to 6 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.
  • Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 12 Months [ Time Frame: Days 0, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600 ]
    Time to first occurrence of >= 30% pain reduction in average back pain from baseline to 12 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.
  • Change From Baseline to 3-Month Endpoint in the Roland-Morris Disability Questionnaire. [ Time Frame: Baseline, 3 Months ]
    Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).
  • Change From Baseline to 6-Month Endpoint in the Roland-Morris Disability Questionnaire. [ Time Frame: Baseline, 6 Months ]
    Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).
  • Change From Baseline to 12-Month Endpoint in the Roland-Morris Disability Questionnaire. [ Time Frame: Baseline, 12 Months ]
    Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability).
  • Change From Baseline to 6-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO) [ Time Frame: Baseline, 6 Months ]
    QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.
  • Change From Baseline to 12-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO) [ Time Frame: Baseline, 12 Months ]
    QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.
  • Number of Participants With Adverse Events (Safety) During 12 Months [ Time Frame: Baseline through 12 Months ]
    Safety was assessed via serious adverse events and all other non-serious adverse events and the data are located in the Reported Adverse Events Section.
  • Number of Participants With Adverse Events (Safety) During 18 Months [ Time Frame: Baseline through 18 Months ]
    Safety is assessed via serious adverse events and all other non-serious adverse events and the data are located in the Reported Adverse Events Section.
  • Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 18-Month Endpoint [ Time Frame: 18 Months ]
    24-hour worst back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of worst back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of worst back pain from baseline to the 18-month last observation carried forward (LOCF) endpoint.
  • Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 18-Month Endpoint [ Time Frame: 18 Months ]
    24-hour average back pain severity scores recorded daily on an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The 11-point scale is used for assessment of average back pain in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. Responders are defined as participants with at least a 30% reduction in the severity of average back pain from baseline to the 18-month last observation carried forward (LOCF) endpoint.
  • Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 18 Months [ Time Frame: Baseline through 18 Months ]
    Time to first occurrence of >= 30% pain reduction in worst back pain from baseline to 18 months. Worst back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the worst back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of worst back pain up to time (t) in days.
  • Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 18 Months [ Time Frame: Baseline through 18 Months ]
    Time to first occurrence of >=30% pain reduction in average back pain from baseline to 18 months. Average back pain is assessed using an 11-point numeric rating scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain), to rate the average back pain experienced in the preceding 24 hours and is evaluated daily in the week prior to each scheduled study visit. The results are reported as the number of participants reporting at least a 30% reduction in the severity of average back pain up to time (t) in days.
  • Change From Baseline to 18-Month Endpoint in the Roland-Morris Disability Questionnaire. [ Time Frame: Baseline, 18 Months ]
    Roland-Morris Disability Questionnaire (RMDQ-24) is completed by the participant and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement. The number of statements marked are added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability). Pooled site, baseline glucocorticoid usage status (yes/no) and baseline score were controlled for.
  • Change From Baseline to 18-Month Endpoint in European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO) [ Time Frame: Baseline, 18 Months ]
    QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life.
  • Proportion of patients treated with at least a 30% reduction in the severity of worst back pain will be assessed using the mean score from the 11-point numeric rating scale from baseline to 12 and 18 months
  • Proportion of patients treated with at least a 30% reduction in the severity of average back pain will be assessed using the mean score from the 11-point numeric rating scale from baseline to 6, 12, and 18 months
  • Time to first occurrence of the proportion of patients treated with at least a 30% reduction for both worst and average back pain will be assessed using the mean score from the 11-point numeric rating scale from baseline to 6, 12, and 18 months
  • The measure for the effect on daily living activities as assessed by the Roland Disability Questionnaire will be the mean change in Roland score from baseline to 3, 6, 12, and 18 months
  • The measure on quality of life as assessed by QUALEFFO will be the mean change is score from baseline to 6, 12, and 18 months
Not Provided
Not Provided
 
Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures
The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Osteoporosis, Postmenopausal
  • Back Pain
  • Spinal Fracture
  • Drug: teriparatide
    20 ug/day, subcutaneous, 18 months
    Other Names:
    • LY333334
    • Forteo
    • Forsteo
  • Drug: risedronate
    35 mg/once weekly, oral, 18 months
    Other Name: Actonel
  • Drug: placebo
    once weekly, oral, 18 months
    Other Names:
    • LY333334
    • Forteo
    • Forsteo
  • Drug: placebo
    daily, subcutaneous, 18 months
    Other Name: Actonel
  • Experimental: Teriparatide
    Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
    Interventions:
    • Drug: teriparatide
    • Drug: placebo
  • Active Comparator: Risedronate
    Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
    Interventions:
    • Drug: risedronate
    • Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
712
546
June 2010
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postmenopausal women 45 years or older. No period for at least two years.
  • History of back pain that started at least 2 months prior to the initial visit (likely due to spinal bone fracture determined by investigator).
  • Minimum of one moderate spinal bone fracture.
  • Beginning pain level of at least four on an eleven point scale.
  • Bone Mineral Density (BMD) must meet criteria
  • Able to read, understand, and administer self-questionnaires.
  • Be willing and able to use a pen-injector to deliver the medication.

Exclusion Criteria:

  • Are at increased risk for osteosarcoma.
  • Have an active or suspected diseases that affects bone metabolism other than osteoporosis.
  • Participants that already know that they will require procedures to repair their spinal bone fractures.
  • Abnormal values of certain lab tests.
  • Anything that would make it difficult to determine if the back pain was due to the fracture.
  • Poor medical or psychiatric condition.
  • Alcohol or drug abuse within a year of the study start.
  • Certain malignant neoplasms in the 5 years prior to enrollment.
  • Active liver disease or clinical jaundice.
  • Significantly impaired renal function.
  • History of nephrolithiasis or urolithiasis within 2 years prior to enrollment.
  • Known contraindication or intolerance to risedronate and/or teriparatide therapy.
  • Treatment with oral strontium or certain therapeutic doses of fluoride.
Sexes Eligible for Study: Female
45 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Belgium,   Brazil,   Canada,   France,   Germany,   Italy,   Mexico,   Puerto Rico,   Spain,   Sweden,   United States
 
 
NCT00343252
9041
B3D-MC-GHCY ( Other Identifier: Eli Lilly and Company )
No
Not Provided
Not Provided
Chief Medical Officer, Eli Lilly
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP